Objectives 4CMenB is a broadly protective vaccine against invasive meningococcal
capsular group B disease (MenB IMD). Licensed worldwide based on immunogenicity and …

Recently approved in Europe and Australia, the multi-component meningococcal B vaccine,
4CMenB (Bexsero®, Novartis Vaccines and Diagnostics), contains three surface-exposed …

Abstract Background In September 2015, the United Kingdom introduced the
multicomponent meningococcal group B vaccine (4CMenB, Bexsero) into its publicly funded …

Abstract Background In September 2015, the four-component, protein-based meningococcal
serogroup B vaccine (4CMenB; Bexsero) became available for private purchase in Spain …

Introduction Neisseria meningitidis causes invasive meningococcal disease and, globally,
significant morbidity, with serogroup B (MenB) being the most common cause of endemic …

Introduction: The successful development of two broadly protective vaccines targeting
Neisseria meningitidis serogroup B (MenB); 4CMenB and rLP2086, is the most significant …

Background The multicomponent meningococcal serogroup B vaccine (4CMenB) has been
licensed in more than 35 countries. However, uncertainties remain about the lowest number …

Although rare, invasive meningococcal disease remains an important cause of mortality and
morbidity in children and young adults. Vaccines have been successfully introduced to help …

Respiratory viral pathogens like influenza and coronaviruses such as severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) have caused outbreaks leading to …

Invasive meningococcal disease (IMD) is a major public health concern because of its high
case fatality, long-term morbidity, and potential to course with outbreaks. IMD caused by …